Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0001599298-23-000103

Chief Executive Officer bought 5,000 shares at $2.07 ($10,350)

  • Chief Executive Officer acquired 805,495 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Zanganeh Mahkam · Chief Executive Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-12-11 Option exercise : show line 1 in the form +489,814 $1.44 $705,332 489,814 D
2023-12-12 Purchase : show line 2 in the form +5,000 $2.07 $10,350 494,814 D
2023-12-11 Option exercise : show line 3 in the form +315,681 $1.58 $498,776 24,889,479 I
Open-market purchases · 5,000 sh · avg $2.07 · $10,350

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2023-12-11 Option exercise : show line 4 in the form Warrant (right to buy) −489,814 0 D
2023-12-11 Option exercise : show line 5 in the form Warrant (right to buy) −315,681 0 I
Loading xslF345X05/wk-form4_1702505507.xml…